department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Akynzeo · pharmadog

pharmadog
drugs
Akynzeo

drug

patient view →

(netupitant + palonosetron hydrochloride)

Marketedupdated 2mo ago

by Helsinn Therapeutics (US) Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Akynzeo

generic

(netupitant + palonosetron hydrochloride)

indication

Chemotherapy Induced Nausea and Vomiting

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 6m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying (netupitant + palonosetron hydrochloride)

phase1A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteersterminatedn=50
phase2Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapyunknownn=100